Search

PHARMA MAR, S.A.

Page 1 out of 2

from 10/10/2017 to 18/01/2018

The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish

    • 18/01/2018
    • 19:00
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • CORAIL Phase III with Zepsire in resistant ovarian cancer has not met its primary endpoint.
    • Register number: 260786
    • Price sensitive information of PHARMA MAR, S.A.
    • 11/01/2018
    • 17:58
    • PHARMA MAR, S.A.
    • Liquidity contracts and specialists
    • The Company reports details of the operations of the Liquidity Agreement between 11/10/2017 and 10/01/2018
    • Register number: 260607
    • Price sensitive information of PHARMA MAR, S.A.
    • 09/01/2018
    • 14:13
    • PHARMA MAR, S.A.
    • Strategic plans, profit forecasts and presentations
    • New corporate presentation (English version) which will be available in the Company´s web site.
    • Register number: 260513
    • Price sensitive information of PHARMA MAR, S.A.
    • 03/01/2018
    • 09:24
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • In relation to the Significant Fact n. 259611, PharmaMar has requested from the European Medicines Agency the re-examination of the negative Opinion issued by the CHMP for Aplidin® for the indication of relapsed and refractory multiple myeloma.
    • Register number: 260272
    • Price sensitive information of PHARMA MAR, S.A.
    • 15/12/2017
    • 12:43
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • In relation to the Significant Fact n. 258359, the CHMP of EMA has finally emitted its opinion against the approval of Aplidin® in multiple myeloma.
    • Register number: 259611
    • Price sensitive information of PHARMA MAR, S.A.
    • 11/12/2017
    • 08:18
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • In relation to Significant Fact n 236.798, presentation of results from ADMYRE Phase III trial of plitidepsin in multiple myeloma at the 59th American Society of Hematology annual Meeting & Exposition.
    • Register number: 259246
    • Price sensitive information of PHARMA MAR, S.A.
    • 15/11/2017
    • 08:12
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • After analysis of the safety data of the first 150 patients, IDMC recommends that the Phase III trial with Zepsyre® in small-cell lung cancer patients should continue without any changes
    • Register number: 258531
    • Price sensitive information of PHARMA MAR, S.A.
    • 14/11/2017
    • 08:09
    • PHARMA MAR, S.A.
    • Announcements of public presentations and meetings
    • Pharma Mar will participate in the Stifel Nicolaus Weisel Healthcare Conference to be held in New York on Nov. 15.
    • Register number: 258469
    • Price sensitive information of PHARMA MAR, S.A.
    • 08/11/2017
    • 19:31
    • PHARMA MAR, S.A.
    • R&D: new licenses, patents and registered trademarks
    • Pharma Mar announces CHMP negative trend vote in relation to Aplidin Marketing Authorization Application for multiple myeloma.
    • Register number: 258359
    • Price sensitive information of PHARMA MAR, S.A.
    • 24/10/2017
    • 17:49
    • PHARMA MAR, S.A.
    • Information on P&L
    • The Company sends press release regarding the third quarter 2017 results.
    • Register number: 257730
    • Price sensitive information of PHARMA MAR, S.A.
Page 1 out of 2

The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish.